Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carpal Tunnel Syndrome | 11 | 2022 | 305 | 4.890 |
Why?
|
Orthopedics | 14 | 2023 | 900 | 4.460 |
Why?
|
Herpes Genitalis | 10 | 2022 | 148 | 3.980 |
Why?
|
Herpes Simplex Virus Vaccines | 6 | 2022 | 17 | 3.450 |
Why?
|
Orthopedic Procedures | 11 | 2023 | 1280 | 3.210 |
Why?
|
Herpesvirus 2, Human | 9 | 2022 | 191 | 2.460 |
Why?
|
Hand | 11 | 2022 | 907 | 2.280 |
Why?
|
Cytomegalovirus Vaccines | 4 | 2020 | 20 | 2.020 |
Why?
|
Ankle | 4 | 2023 | 353 | 1.820 |
Why?
|
Viral Envelope Proteins | 8 | 2022 | 640 | 1.760 |
Why?
|
Adjuvants, Immunologic | 11 | 2025 | 995 | 1.540 |
Why?
|
Influenza Vaccines | 10 | 2025 | 778 | 1.540 |
Why?
|
Cytomegalovirus Infections | 9 | 2020 | 835 | 1.520 |
Why?
|
Antibodies, Viral | 23 | 2025 | 3211 | 1.450 |
Why?
|
Virus Shedding | 8 | 2019 | 111 | 1.370 |
Why?
|
Bronchodilator Agents | 3 | 2020 | 514 | 1.360 |
Why?
|
Spinal Fusion | 6 | 2024 | 1303 | 1.330 |
Why?
|
Upper Extremity | 6 | 2021 | 682 | 1.320 |
Why?
|
Patient Satisfaction | 11 | 2023 | 3478 | 1.310 |
Why?
|
Management Information Systems | 2 | 2019 | 49 | 1.250 |
Why?
|
Arthroplasty, Replacement, Knee | 6 | 2023 | 1379 | 1.240 |
Why?
|
Vaccination | 11 | 2022 | 3427 | 1.210 |
Why?
|
Androstadienes | 3 | 2020 | 347 | 1.110 |
Why?
|
Chlorobenzenes | 2 | 2018 | 31 | 1.090 |
Why?
|
Benzyl Alcohols | 2 | 2018 | 33 | 1.090 |
Why?
|
Specialties, Surgical | 2 | 2022 | 391 | 1.070 |
Why?
|
Immunization Schedule | 5 | 2018 | 228 | 0.990 |
Why?
|
Isocyanates | 2 | 2015 | 12 | 0.970 |
Why?
|
Papillomavirus Vaccines | 5 | 2019 | 495 | 0.970 |
Why?
|
Foot | 2 | 2019 | 573 | 0.960 |
Why?
|
Lumbar Vertebrae | 3 | 2024 | 1874 | 0.950 |
Why?
|
Cytomegalovirus | 6 | 2020 | 751 | 0.930 |
Why?
|
Papillomavirus Infections | 7 | 2019 | 1638 | 0.910 |
Why?
|
Arthroplasty, Replacement, Hip | 3 | 2020 | 1416 | 0.900 |
Why?
|
Viral Vaccines | 5 | 2019 | 597 | 0.880 |
Why?
|
Guinea Pigs | 7 | 2022 | 1300 | 0.870 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2022 | 452 | 0.860 |
Why?
|
Humans | 169 | 2025 | 765734 | 0.820 |
Why?
|
Musculoskeletal Diseases | 3 | 2023 | 598 | 0.790 |
Why?
|
Pain Measurement | 5 | 2019 | 3559 | 0.780 |
Why?
|
Spinal Curvatures | 2 | 2019 | 71 | 0.720 |
Why?
|
Herpesvirus 1, Human | 3 | 2022 | 743 | 0.720 |
Why?
|
Herpes Simplex | 2 | 2022 | 471 | 0.720 |
Why?
|
Hospital Costs | 3 | 2024 | 956 | 0.710 |
Why?
|
Antibody Formation | 4 | 2018 | 1391 | 0.700 |
Why?
|
Allergens | 4 | 2018 | 1436 | 0.700 |
Why?
|
Personal Satisfaction | 2 | 2023 | 641 | 0.680 |
Why?
|
Fractures, Spontaneous | 1 | 2022 | 230 | 0.680 |
Why?
|
Ossification of Posterior Longitudinal Ligament | 1 | 2019 | 17 | 0.680 |
Why?
|
Cervical Vertebrae | 4 | 2021 | 978 | 0.670 |
Why?
|
Hepatitis, Viral, Human | 1 | 2020 | 141 | 0.660 |
Why?
|
Asthma | 7 | 2024 | 6269 | 0.660 |
Why?
|
Dissection | 1 | 2021 | 299 | 0.660 |
Why?
|
Nebulizers and Vaporizers | 1 | 2020 | 138 | 0.650 |
Why?
|
Female | 101 | 2025 | 395961 | 0.640 |
Why?
|
Vehicle Emissions | 2 | 2014 | 651 | 0.640 |
Why?
|
Insurance | 1 | 2021 | 115 | 0.640 |
Why?
|
Depression | 10 | 2022 | 8230 | 0.640 |
Why?
|
Disability Evaluation | 5 | 2023 | 1820 | 0.640 |
Why?
|
Escherichia coli Vaccines | 1 | 2018 | 10 | 0.630 |
Why?
|
Delivery of Health Care | 6 | 2023 | 5368 | 0.630 |
Why?
|
Spinal Diseases | 3 | 2022 | 560 | 0.630 |
Why?
|
Enterotoxigenic Escherichia coli | 1 | 2018 | 32 | 0.620 |
Why?
|
Spine | 4 | 2022 | 1129 | 0.620 |
Why?
|
Arthroplasty, Replacement | 1 | 2022 | 314 | 0.610 |
Why?
|
Liver Function Tests | 1 | 2020 | 526 | 0.610 |
Why?
|
Neck Pain | 1 | 2020 | 190 | 0.610 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 480 | 0.610 |
Why?
|
Femoral Neck Fractures | 1 | 2020 | 143 | 0.600 |
Why?
|
Pain | 8 | 2022 | 5074 | 0.600 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2025 | 163 | 0.590 |
Why?
|
Sports Medicine | 1 | 2020 | 239 | 0.580 |
Why?
|
Antigens, Dermatophagoides | 1 | 2018 | 101 | 0.580 |
Why?
|
Medical History Taking | 1 | 2021 | 778 | 0.580 |
Why?
|
Diagnostic Self Evaluation | 1 | 2019 | 228 | 0.570 |
Why?
|
Middle Aged | 63 | 2025 | 222903 | 0.570 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 297 | 0.570 |
Why?
|
Periodicals as Topic | 4 | 2021 | 1462 | 0.570 |
Why?
|
Virion | 1 | 2019 | 430 | 0.560 |
Why?
|
Testicular Neoplasms | 1 | 2023 | 786 | 0.560 |
Why?
|
Double-Blind Method | 16 | 2024 | 12433 | 0.550 |
Why?
|
Enterotoxins | 1 | 2018 | 366 | 0.550 |
Why?
|
Wrist Injuries | 1 | 2019 | 215 | 0.550 |
Why?
|
Male | 82 | 2025 | 363585 | 0.550 |
Why?
|
Vaccines, Inactivated | 5 | 2025 | 185 | 0.550 |
Why?
|
Socioeconomic Factors | 3 | 2022 | 7835 | 0.550 |
Why?
|
Conjunctivitis | 1 | 2018 | 153 | 0.540 |
Why?
|
Spinal Injuries | 1 | 2020 | 300 | 0.540 |
Why?
|
Vaccines, Attenuated | 6 | 2022 | 312 | 0.540 |
Why?
|
Hand Injuries | 1 | 2019 | 239 | 0.540 |
Why?
|
Mentors | 1 | 2022 | 671 | 0.520 |
Why?
|
Patient Readmission | 4 | 2024 | 3286 | 0.520 |
Why?
|
Career Mobility | 1 | 2018 | 259 | 0.520 |
Why?
|
Office Visits | 2 | 2019 | 594 | 0.520 |
Why?
|
Influenza, Human | 6 | 2025 | 1537 | 0.520 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 430 | 0.510 |
Why?
|
Spinal Neoplasms | 2 | 2019 | 708 | 0.510 |
Why?
|
Achilles Tendon | 1 | 2018 | 181 | 0.510 |
Why?
|
Recovery of Function | 7 | 2022 | 2965 | 0.510 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 672 | 0.510 |
Why?
|
Adolescent | 43 | 2025 | 88781 | 0.510 |
Why?
|
Adult | 63 | 2025 | 222974 | 0.510 |
Why?
|
Tendinopathy | 1 | 2018 | 174 | 0.500 |
Why?
|
Aged | 45 | 2025 | 171050 | 0.500 |
Why?
|
Postoperative Complications | 7 | 2022 | 15749 | 0.500 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2015 | 87 | 0.490 |
Why?
|
Extremities | 1 | 2021 | 869 | 0.490 |
Why?
|
Vulnerable Populations | 1 | 2021 | 718 | 0.490 |
Why?
|
Mental Health | 4 | 2023 | 3272 | 0.490 |
Why?
|
Vaccines, Subunit | 4 | 2022 | 158 | 0.490 |
Why?
|
Attitude | 1 | 2020 | 770 | 0.490 |
Why?
|
Anthrax Vaccines | 1 | 2014 | 13 | 0.480 |
Why?
|
Viral Matrix Proteins | 1 | 2016 | 192 | 0.470 |
Why?
|
Schools, Medical | 1 | 2021 | 877 | 0.470 |
Why?
|
Antibodies, Neutralizing | 7 | 2022 | 2010 | 0.470 |
Why?
|
Decompression, Surgical | 1 | 2019 | 603 | 0.460 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.460 |
Why?
|
Burnout, Professional | 1 | 2023 | 710 | 0.450 |
Why?
|
Anthrax | 1 | 2014 | 83 | 0.450 |
Why?
|
Parainfluenza Virus 3, Human | 2 | 2011 | 25 | 0.450 |
Why?
|
Bibliometrics | 4 | 2021 | 355 | 0.440 |
Why?
|
Patient Participation | 1 | 2023 | 1455 | 0.440 |
Why?
|
Biological Products | 1 | 2023 | 942 | 0.440 |
Why?
|
Hip Prosthesis | 1 | 2020 | 895 | 0.440 |
Why?
|
Genes, MHC Class I | 1 | 2014 | 236 | 0.430 |
Why?
|
Clinical Protocols | 2 | 2018 | 1441 | 0.430 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2014 | 113 | 0.430 |
Why?
|
Bacterial Toxins | 1 | 2018 | 924 | 0.420 |
Why?
|
Genes, MHC Class II | 1 | 2014 | 433 | 0.420 |
Why?
|
Young Adult | 32 | 2025 | 59852 | 0.420 |
Why?
|
Vagina | 1 | 2018 | 848 | 0.410 |
Why?
|
Papillomaviridae | 3 | 2018 | 1137 | 0.410 |
Why?
|
Ambulatory Care Facilities | 1 | 2019 | 939 | 0.400 |
Why?
|
Quality of Life | 7 | 2023 | 13462 | 0.400 |
Why?
|
Fracture Fixation, Internal | 4 | 2023 | 982 | 0.390 |
Why?
|
Parainfluenza Vaccines | 1 | 2011 | 1 | 0.380 |
Why?
|
Escherichia coli Proteins | 1 | 2018 | 1057 | 0.380 |
Why?
|
Retrospective Studies | 26 | 2024 | 81457 | 0.380 |
Why?
|
United States | 24 | 2024 | 72898 | 0.380 |
Why?
|
Scoliosis | 1 | 2019 | 789 | 0.380 |
Why?
|
Erythema Infectiosum | 1 | 2011 | 15 | 0.380 |
Why?
|
Parvovirus B19, Human | 1 | 2011 | 42 | 0.370 |
Why?
|
Health Care Costs | 3 | 2024 | 3242 | 0.370 |
Why?
|
Health Policy | 1 | 2024 | 2699 | 0.370 |
Why?
|
Eosinophils | 3 | 2024 | 945 | 0.370 |
Why?
|
Journal Impact Factor | 3 | 2021 | 157 | 0.370 |
Why?
|
Patient Discharge | 3 | 2021 | 3461 | 0.360 |
Why?
|
Hemagglutinins, Viral | 1 | 2010 | 66 | 0.360 |
Why?
|
Shoulder Joint | 1 | 2017 | 740 | 0.360 |
Why?
|
Administration, Inhalation | 3 | 2020 | 1154 | 0.360 |
Why?
|
Influenza A Virus, H3N2 Subtype | 2 | 2022 | 85 | 0.350 |
Why?
|
Genotype | 7 | 2020 | 13024 | 0.350 |
Why?
|
Disabled Persons | 1 | 2020 | 1208 | 0.350 |
Why?
|
Air Pollution | 2 | 2014 | 2380 | 0.340 |
Why?
|
Treatment Outcome | 23 | 2023 | 65180 | 0.340 |
Why?
|
Saliva | 4 | 2020 | 851 | 0.340 |
Why?
|
Polymorphism, Genetic | 1 | 2020 | 4249 | 0.320 |
Why?
|
Preoperative Care | 1 | 2018 | 2266 | 0.320 |
Why?
|
Health Promotion | 1 | 2021 | 2208 | 0.320 |
Why?
|
Occupational Exposure | 2 | 2014 | 1805 | 0.320 |
Why?
|
Education, Medical | 1 | 2021 | 1746 | 0.320 |
Why?
|
Health Status | 3 | 2023 | 4081 | 0.320 |
Why?
|
Immunization, Secondary | 4 | 2025 | 373 | 0.310 |
Why?
|
Immunity, Cellular | 3 | 2024 | 1554 | 0.310 |
Why?
|
Fatigue Syndrome, Chronic | 1 | 2010 | 217 | 0.300 |
Why?
|
Postoperative Period | 4 | 2024 | 1816 | 0.300 |
Why?
|
Pandemics | 6 | 2022 | 8703 | 0.300 |
Why?
|
Severity of Illness Index | 5 | 2024 | 15883 | 0.300 |
Why?
|
Drug Administration Schedule | 5 | 2024 | 4850 | 0.290 |
Why?
|
General Surgery | 1 | 2019 | 1722 | 0.290 |
Why?
|
Databases, Factual | 7 | 2021 | 8062 | 0.290 |
Why?
|
Quality of Health Care | 2 | 2024 | 4301 | 0.290 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2002 | 0.290 |
Why?
|
Occupational Diseases | 2 | 2014 | 1456 | 0.280 |
Why?
|
Tablets | 2 | 2018 | 149 | 0.280 |
Why?
|
Pyroglyphidae | 2 | 2018 | 94 | 0.280 |
Why?
|
Child | 20 | 2021 | 80499 | 0.280 |
Why?
|
Phosphoproteins | 1 | 2016 | 2445 | 0.270 |
Why?
|
Rotavirus Vaccines | 2 | 2020 | 62 | 0.270 |
Why?
|
Radius Fractures | 2 | 2023 | 516 | 0.270 |
Why?
|
Rotavirus Infections | 2 | 2020 | 85 | 0.270 |
Why?
|
Ganglion Cysts | 3 | 2021 | 27 | 0.270 |
Why?
|
Exanthema | 1 | 2011 | 500 | 0.270 |
Why?
|
Rotavirus | 2 | 2020 | 110 | 0.260 |
Why?
|
Environmental Pollutants | 1 | 2015 | 1291 | 0.260 |
Why?
|
Neurosurgical Procedures | 1 | 2017 | 2081 | 0.260 |
Why?
|
Eosinophilia | 2 | 2024 | 555 | 0.250 |
Why?
|
Crime Victims | 1 | 2010 | 347 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3101 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3224 | 0.250 |
Why?
|
Cohort Studies | 11 | 2023 | 41631 | 0.250 |
Why?
|
Health Expenditures | 3 | 2024 | 2386 | 0.240 |
Why?
|
Self Report | 3 | 2023 | 3772 | 0.240 |
Why?
|
Penicillium | 2 | 2015 | 23 | 0.240 |
Why?
|
Aged, 80 and over | 12 | 2022 | 59459 | 0.240 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3247 | 0.240 |
Why?
|
Placebos | 5 | 2020 | 1659 | 0.240 |
Why?
|
Reproducibility of Results | 6 | 2023 | 20120 | 0.240 |
Why?
|
Squalene | 3 | 2025 | 36 | 0.230 |
Why?
|
Immunoglobulin A | 3 | 2018 | 992 | 0.230 |
Why?
|
Polysorbates | 3 | 2025 | 46 | 0.230 |
Why?
|
Neuraminidase | 1 | 2025 | 190 | 0.230 |
Why?
|
Wrist | 3 | 2021 | 230 | 0.230 |
Why?
|
Trigger Finger Disorder | 3 | 2019 | 53 | 0.230 |
Why?
|
Osteoarthritis | 2 | 2022 | 1050 | 0.220 |
Why?
|
Prospective Studies | 14 | 2022 | 54795 | 0.210 |
Why?
|
Drug Combinations | 3 | 2025 | 2075 | 0.210 |
Why?
|
Latex Hypersensitivity | 1 | 2003 | 14 | 0.210 |
Why?
|
Internship and Residency | 2 | 2020 | 5946 | 0.210 |
Why?
|
Gloves, Protective | 1 | 2003 | 23 | 0.210 |
Why?
|
Carpometacarpal Joints | 2 | 2021 | 58 | 0.210 |
Why?
|
Rotator Cuff | 2 | 2023 | 348 | 0.210 |
Why?
|
Osteoarthritis, Knee | 2 | 2023 | 1248 | 0.210 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3733 | 0.200 |
Why?
|
Polymerase Chain Reaction | 4 | 2017 | 6061 | 0.200 |
Why?
|
Cross-Sectional Studies | 8 | 2022 | 26284 | 0.200 |
Why?
|
Immune Tolerance | 1 | 2011 | 2324 | 0.200 |
Why?
|
Vaccines, Synthetic | 3 | 2015 | 621 | 0.190 |
Why?
|
Arthroscopy | 3 | 2023 | 967 | 0.190 |
Why?
|
Administration, Intranasal | 3 | 2019 | 482 | 0.190 |
Why?
|
Lung | 1 | 2020 | 10031 | 0.190 |
Why?
|
Inhalation Exposure | 2 | 2014 | 432 | 0.180 |
Why?
|
Cost Control | 1 | 2023 | 625 | 0.180 |
Why?
|
Aptitude Tests | 1 | 2020 | 20 | 0.180 |
Why?
|
Accounting | 1 | 2020 | 25 | 0.180 |
Why?
|
Costs and Cost Analysis | 2 | 2024 | 1669 | 0.180 |
Why?
|
Neutrophils | 1 | 2013 | 3772 | 0.180 |
Why?
|
Antibodies, Bacterial | 2 | 2018 | 1473 | 0.180 |
Why?
|
Air Pollutants | 1 | 2014 | 2923 | 0.180 |
Why?
|
Skin Tests | 3 | 2015 | 630 | 0.170 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2020 | 64 | 0.170 |
Why?
|
Hemagglutination Inhibition Tests | 4 | 2023 | 87 | 0.170 |
Why?
|
Viral Load | 3 | 2020 | 3385 | 0.170 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1880 | 0.170 |
Why?
|
Licensure, Medical | 1 | 2020 | 72 | 0.170 |
Why?
|
Hypersensitivity, Immediate | 1 | 2003 | 346 | 0.170 |
Why?
|
Telemedicine | 3 | 2022 | 3105 | 0.170 |
Why?
|
Licensure | 1 | 2020 | 128 | 0.170 |
Why?
|
Povidone-Iodine | 1 | 2019 | 54 | 0.160 |
Why?
|
Physical Therapy Modalities | 1 | 2023 | 533 | 0.160 |
Why?
|
Administration, Intravaginal | 1 | 2019 | 149 | 0.160 |
Why?
|
Neck Muscles | 1 | 2020 | 100 | 0.160 |
Why?
|
Anti-Asthmatic Agents | 1 | 2024 | 572 | 0.160 |
Why?
|
Seroepidemiologic Studies | 2 | 2018 | 404 | 0.160 |
Why?
|
Information Systems | 1 | 2021 | 400 | 0.160 |
Why?
|
Platelet-Rich Plasma | 1 | 2022 | 180 | 0.160 |
Why?
|
Emulsions | 1 | 2019 | 150 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 4 | 2018 | 3230 | 0.160 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 5526 | 0.160 |
Why?
|
Surgical Wound Infection | 2 | 2019 | 1543 | 0.160 |
Why?
|
Tendon Injuries | 1 | 2022 | 329 | 0.160 |
Why?
|
Administration, Sublingual | 1 | 2018 | 60 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 16041 | 0.160 |
Why?
|
Elbow Joint | 1 | 2022 | 357 | 0.160 |
Why?
|
Gastroenteritis | 1 | 2020 | 229 | 0.160 |
Why?
|
Length of Stay | 4 | 2021 | 6487 | 0.160 |
Why?
|
Antigens, Viral | 2 | 2015 | 995 | 0.160 |
Why?
|
Knee Injuries | 1 | 2023 | 494 | 0.150 |
Why?
|
Vero Cells | 1 | 2019 | 481 | 0.150 |
Why?
|
Personnel Selection | 1 | 2020 | 201 | 0.150 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2018 | 355 | 0.150 |
Why?
|
Animals | 13 | 2022 | 168731 | 0.150 |
Why?
|
Norway | 1 | 2020 | 499 | 0.150 |
Why?
|
Virology | 2 | 2015 | 77 | 0.150 |
Why?
|
Health Facilities | 1 | 2023 | 577 | 0.150 |
Why?
|
Time Factors | 6 | 2020 | 40066 | 0.150 |
Why?
|
Computers | 1 | 2020 | 588 | 0.150 |
Why?
|
Immunoglobulin G | 4 | 2018 | 4527 | 0.150 |
Why?
|
Disclosure | 1 | 2024 | 756 | 0.150 |
Why?
|
Pain, Postoperative | 2 | 2018 | 1771 | 0.140 |
Why?
|
T-Lymphocytes | 3 | 2024 | 10262 | 0.140 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 427 | 0.140 |
Why?
|
Bone Screws | 1 | 2021 | 533 | 0.140 |
Why?
|
Forced Expiratory Volume | 2 | 2024 | 1827 | 0.140 |
Why?
|
Human papillomavirus 18 | 1 | 2018 | 125 | 0.140 |
Why?
|
Ambrosia | 1 | 2017 | 7 | 0.140 |
Why?
|
Physical Examination | 1 | 2023 | 1264 | 0.140 |
Why?
|
Poaceae | 1 | 2017 | 24 | 0.140 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2018 | 109 | 0.140 |
Why?
|
Awards and Prizes | 1 | 2021 | 364 | 0.140 |
Why?
|
Marfan Syndrome | 1 | 2019 | 237 | 0.140 |
Why?
|
Policy | 1 | 2021 | 511 | 0.140 |
Why?
|
Accreditation | 1 | 2020 | 477 | 0.140 |
Why?
|
Fee-for-Service Plans | 1 | 2022 | 716 | 0.140 |
Why?
|
Kyphosis | 1 | 2020 | 251 | 0.140 |
Why?
|
Orthomyxoviridae | 1 | 2018 | 147 | 0.140 |
Why?
|
Odds Ratio | 3 | 2018 | 9647 | 0.140 |
Why?
|
Financing, Organized | 1 | 2018 | 201 | 0.140 |
Why?
|
Waiting Lists | 1 | 2022 | 777 | 0.140 |
Why?
|
Receptors, Chemokine | 1 | 2020 | 651 | 0.140 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2020 | 418 | 0.130 |
Why?
|
Patient Compliance | 2 | 2009 | 2692 | 0.130 |
Why?
|
Postoperative Hemorrhage | 1 | 2020 | 413 | 0.130 |
Why?
|
Roseolovirus | 1 | 2016 | 2 | 0.130 |
Why?
|
Vancomycin | 1 | 2019 | 504 | 0.130 |
Why?
|
Glycoproteins | 2 | 2022 | 2194 | 0.130 |
Why?
|
Empathy | 1 | 2021 | 474 | 0.130 |
Why?
|
Liposomes | 2 | 2011 | 787 | 0.130 |
Why?
|
Hospitals | 2 | 2021 | 3889 | 0.130 |
Why?
|
Perioperative Period | 1 | 2017 | 251 | 0.130 |
Why?
|
Preoperative Period | 1 | 2018 | 566 | 0.130 |
Why?
|
Specialization | 1 | 2021 | 778 | 0.130 |
Why?
|
Laminectomy | 1 | 2017 | 227 | 0.130 |
Why?
|
Sex Factors | 3 | 2021 | 10605 | 0.130 |
Why?
|
Urology | 1 | 2021 | 384 | 0.130 |
Why?
|
Dry Powder Inhalers | 1 | 2015 | 8 | 0.130 |
Why?
|
Surgical Wound Dehiscence | 1 | 2017 | 215 | 0.130 |
Why?
|
Research Design | 3 | 2020 | 6207 | 0.120 |
Why?
|
Acer | 1 | 2015 | 3 | 0.120 |
Why?
|
Risk Factors | 9 | 2022 | 74831 | 0.120 |
Why?
|
Diskectomy | 1 | 2017 | 203 | 0.120 |
Why?
|
Immunity, Humoral | 1 | 2019 | 605 | 0.120 |
Why?
|
Affect | 2 | 2020 | 1498 | 0.120 |
Why?
|
Health Care Surveys | 2 | 2021 | 2425 | 0.120 |
Why?
|
Lymphocytic choriomeningitis virus | 1 | 2016 | 175 | 0.120 |
Why?
|
Quality Improvement | 2 | 2021 | 3854 | 0.120 |
Why?
|
Alphapapillomavirus | 1 | 2018 | 219 | 0.120 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2015 | 57 | 0.120 |
Why?
|
Alternaria | 1 | 2014 | 41 | 0.120 |
Why?
|
Escherichia coli Infections | 1 | 2018 | 519 | 0.120 |
Why?
|
Triage | 1 | 2021 | 996 | 0.120 |
Why?
|
Pruritus | 1 | 2018 | 378 | 0.120 |
Why?
|
Health Care Reform | 1 | 2024 | 1259 | 0.110 |
Why?
|
Spain | 1 | 2015 | 483 | 0.110 |
Why?
|
Activities of Daily Living | 2 | 2023 | 2415 | 0.110 |
Why?
|
Urine | 1 | 2015 | 360 | 0.110 |
Why?
|
Histamine H1 Antagonists | 2 | 2005 | 100 | 0.110 |
Why?
|
Low Back Pain | 1 | 2022 | 987 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2021 | 1383 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 18061 | 0.110 |
Why?
|
Hepatitis C, Chronic | 1 | 2002 | 1032 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2019 | 811 | 0.110 |
Why?
|
Inflammation | 1 | 2013 | 10846 | 0.110 |
Why?
|
Health Services Research | 1 | 2021 | 1810 | 0.110 |
Why?
|
Neurofibromatosis 1 | 1 | 2018 | 560 | 0.110 |
Why?
|
Antimalarials | 1 | 2020 | 911 | 0.110 |
Why?
|
Gastrectomy | 1 | 2018 | 694 | 0.110 |
Why?
|
Adaptation, Psychological | 2 | 2021 | 2660 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2845 | 0.100 |
Why?
|
Blood | 1 | 2015 | 597 | 0.100 |
Why?
|
Interviews as Topic | 1 | 2020 | 2740 | 0.100 |
Why?
|
Pest Control | 1 | 2012 | 29 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2018 | 4057 | 0.100 |
Why?
|
Immunotherapy | 2 | 2019 | 4752 | 0.100 |
Why?
|
Ohio | 1 | 2013 | 320 | 0.100 |
Why?
|
Survivors | 1 | 2023 | 2374 | 0.100 |
Why?
|
Viral Proteins | 1 | 2020 | 1798 | 0.100 |
Why?
|
DNA, Viral | 3 | 2015 | 2199 | 0.100 |
Why?
|
Data Mining | 1 | 2017 | 562 | 0.100 |
Why?
|
Medicare | 2 | 2021 | 6821 | 0.100 |
Why?
|
Protein-Energy Malnutrition | 1 | 2013 | 189 | 0.100 |
Why?
|
Fever | 1 | 2020 | 1602 | 0.100 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1171 | 0.100 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1792 | 0.100 |
Why?
|
Athletic Injuries | 1 | 2022 | 1244 | 0.100 |
Why?
|
Ischemia | 1 | 2021 | 1910 | 0.100 |
Why?
|
Career Choice | 1 | 2018 | 769 | 0.100 |
Why?
|
Logistic Models | 2 | 2017 | 13261 | 0.100 |
Why?
|
Administration, Oral | 2 | 2018 | 4015 | 0.100 |
Why?
|
Liver Diseases | 1 | 2020 | 1303 | 0.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 1559 | 0.090 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 967 | 0.090 |
Why?
|
Self Care | 1 | 2017 | 800 | 0.090 |
Why?
|
Leadership | 1 | 2021 | 1392 | 0.090 |
Why?
|
Health Literacy | 1 | 2017 | 465 | 0.090 |
Why?
|
Child, Preschool | 8 | 2019 | 42468 | 0.090 |
Why?
|
Cost of Illness | 1 | 2021 | 1949 | 0.090 |
Why?
|
Rodentia | 1 | 2012 | 261 | 0.090 |
Why?
|
Age Factors | 2 | 2018 | 18375 | 0.090 |
Why?
|
Sputum | 1 | 2013 | 513 | 0.090 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18289 | 0.090 |
Why?
|
Educational Status | 1 | 2018 | 2513 | 0.090 |
Why?
|
Food Hypersensitivity | 1 | 2018 | 737 | 0.090 |
Why?
|
Interferon-alpha | 2 | 2007 | 910 | 0.090 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2017 | 781 | 0.090 |
Why?
|
ROC Curve | 1 | 2018 | 3618 | 0.090 |
Why?
|
Infant | 8 | 2020 | 36363 | 0.090 |
Why?
|
Peroxidase | 1 | 2013 | 605 | 0.090 |
Why?
|
Animals, Newborn | 1 | 2016 | 2670 | 0.090 |
Why?
|
Canada | 1 | 2015 | 2119 | 0.090 |
Why?
|
Alum Compounds | 1 | 2009 | 35 | 0.080 |
Why?
|
Neonatal Screening | 2 | 2011 | 619 | 0.080 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2021 | 1758 | 0.080 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 1135 | 0.080 |
Why?
|
Genetic Markers | 1 | 2015 | 2601 | 0.080 |
Why?
|
Hospitalization | 4 | 2021 | 10806 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 2020 | 3691 | 0.080 |
Why?
|
Health Personnel | 1 | 2003 | 3390 | 0.080 |
Why?
|
Biomedical Research | 2 | 2021 | 3458 | 0.080 |
Why?
|
Neutralization Tests | 1 | 2011 | 735 | 0.080 |
Why?
|
Cross Reactions | 1 | 2010 | 824 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2022 | 3412 | 0.080 |
Why?
|
De Quervain Disease | 2 | 2018 | 20 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2018 | 997 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9337 | 0.070 |
Why?
|
Risk Assessment | 3 | 2018 | 24279 | 0.070 |
Why?
|
Capsid Proteins | 1 | 2011 | 467 | 0.070 |
Why?
|
Virus Replication | 1 | 2016 | 2447 | 0.070 |
Why?
|
Ganglia, Spinal | 1 | 2011 | 528 | 0.070 |
Why?
|
Virus Latency | 1 | 2011 | 360 | 0.070 |
Why?
|
Patient Selection | 2 | 2021 | 4254 | 0.070 |
Why?
|
Nanoparticles | 1 | 2019 | 1962 | 0.070 |
Why?
|
Internet | 1 | 2020 | 3103 | 0.070 |
Why?
|
Developing Countries | 1 | 2020 | 2912 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2021 | 3800 | 0.070 |
Why?
|
Venous Thrombosis | 1 | 2017 | 1327 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12056 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5343 | 0.070 |
Why?
|
Anxiety | 1 | 2022 | 4670 | 0.070 |
Why?
|
HEK293 Cells | 1 | 2016 | 4255 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10385 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3236 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5876 | 0.070 |
Why?
|
Health Surveys | 1 | 2016 | 4057 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2657 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2009 | 433 | 0.060 |
Why?
|
Respirovirus Infections | 1 | 2005 | 51 | 0.060 |
Why?
|
Dibenzoxepins | 1 | 2005 | 28 | 0.060 |
Why?
|
Mortality | 1 | 2017 | 2904 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3684 | 0.060 |
Why?
|
Ribavirin | 1 | 2007 | 395 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8498 | 0.060 |
Why?
|
Caregivers | 1 | 2018 | 2307 | 0.060 |
Why?
|
Pneumonia | 1 | 2017 | 2156 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 10730 | 0.060 |
Why?
|
Injections, Intramuscular | 2 | 2018 | 553 | 0.060 |
Why?
|
Athletes | 2 | 2023 | 1162 | 0.060 |
Why?
|
Herpesvirus 3, Human | 1 | 2006 | 159 | 0.060 |
Why?
|
Genomics | 1 | 2021 | 5924 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3278 | 0.060 |
Why?
|
Knee Joint | 2 | 2023 | 1657 | 0.060 |
Why?
|
Mass Screening | 2 | 2018 | 5445 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15390 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2024 | 7875 | 0.060 |
Why?
|
Anti-Bacterial Agents | 2 | 2020 | 7477 | 0.060 |
Why?
|
alpha-Tocopherol | 1 | 2025 | 127 | 0.060 |
Why?
|
Nucleoproteins | 1 | 2024 | 110 | 0.060 |
Why?
|
Body Mass Index | 2 | 2019 | 13044 | 0.060 |
Why?
|
Regression Analysis | 1 | 2013 | 6319 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2822 | 0.050 |
Why?
|
Interleukin-5 | 1 | 2024 | 268 | 0.050 |
Why?
|
Loratadine | 1 | 2003 | 14 | 0.050 |
Why?
|
Pulmonary Embolism | 1 | 2017 | 2598 | 0.050 |
Why?
|
Medical Oncology | 1 | 2015 | 2339 | 0.050 |
Why?
|
Hypersensitivity | 1 | 2012 | 1168 | 0.050 |
Why?
|
Infant, Newborn | 7 | 2018 | 26332 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5442 | 0.050 |
Why?
|
Sepsis | 1 | 2017 | 2601 | 0.050 |
Why?
|
Vaccines, Combined | 1 | 2023 | 70 | 0.050 |
Why?
|
Influenza B virus | 1 | 2023 | 53 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 682 | 0.050 |
Why?
|
Spinal Cord | 1 | 2011 | 1783 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4862 | 0.050 |
Why?
|
Vaginal Smears | 1 | 2005 | 506 | 0.050 |
Why?
|
Elbow | 1 | 2022 | 129 | 0.050 |
Why?
|
Algorithms | 2 | 2020 | 14061 | 0.050 |
Why?
|
Risk | 1 | 2014 | 9592 | 0.050 |
Why?
|
Urticaria | 1 | 2003 | 151 | 0.050 |
Why?
|
Environmental Exposure | 2 | 2015 | 4542 | 0.050 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2003 | 112 | 0.050 |
Why?
|
Parents | 1 | 2014 | 3592 | 0.040 |
Why?
|
Influenza A virus | 1 | 2024 | 453 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2024 | 1602 | 0.040 |
Why?
|
Rupture | 1 | 2022 | 444 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39180 | 0.040 |
Why?
|
Comprehensive Health Care | 1 | 2021 | 123 | 0.040 |
Why?
|
Neoplasms | 2 | 2022 | 22345 | 0.040 |
Why?
|
Powders | 1 | 2019 | 78 | 0.040 |
Why?
|
Midwestern United States | 1 | 2019 | 70 | 0.040 |
Why?
|
Wrist Joint | 1 | 2021 | 264 | 0.040 |
Why?
|
Bone Plates | 1 | 2022 | 469 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2021 | 299 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2024 | 3159 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8038 | 0.040 |
Why?
|
Immunologic Memory | 1 | 2006 | 1375 | 0.040 |
Why?
|
Aging | 2 | 2015 | 8730 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2009 | 5879 | 0.040 |
Why?
|
Thumb | 1 | 2021 | 233 | 0.040 |
Why?
|
Medication Adherence | 1 | 2010 | 2190 | 0.040 |
Why?
|
Orthotic Devices | 1 | 2020 | 131 | 0.040 |
Why?
|
Genetic Variation | 1 | 2014 | 6607 | 0.040 |
Why?
|
New York | 1 | 2021 | 880 | 0.040 |
Why?
|
Therapeutic Irrigation | 1 | 2019 | 297 | 0.040 |
Why?
|
Tendons | 1 | 2022 | 555 | 0.040 |
Why?
|
Early Ambulation | 1 | 2018 | 49 | 0.040 |
Why?
|
Pregnancy | 2 | 2021 | 30248 | 0.040 |
Why?
|
Arthroplasty | 1 | 2020 | 306 | 0.040 |
Why?
|
Back Pain | 1 | 2022 | 544 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11080 | 0.040 |
Why?
|
North America | 1 | 2021 | 1285 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 791 | 0.040 |
Why?
|
RNA, Viral | 2 | 2007 | 2865 | 0.040 |
Why?
|
Administration, Topical | 1 | 2019 | 703 | 0.040 |
Why?
|
Sexually Transmitted Diseases | 1 | 2003 | 667 | 0.040 |
Why?
|
Hepatitis C | 1 | 2007 | 1597 | 0.030 |
Why?
|
Injections | 1 | 2020 | 839 | 0.030 |
Why?
|
Neuromuscular Diseases | 1 | 2020 | 260 | 0.030 |
Why?
|
Seasons | 1 | 2023 | 1522 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 590 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6492 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2020 | 493 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2020 | 584 | 0.030 |
Why?
|
Autoantibodies | 1 | 2004 | 2112 | 0.030 |
Why?
|
Obesity | 1 | 2018 | 13079 | 0.030 |
Why?
|
Sex Distribution | 1 | 2021 | 2263 | 0.030 |
Why?
|
Range of Motion, Articular | 1 | 2022 | 1595 | 0.030 |
Why?
|
Prognosis | 3 | 2022 | 29899 | 0.030 |
Why?
|
End Stage Liver Disease | 1 | 2020 | 369 | 0.030 |
Why?
|
Women's Health | 1 | 2005 | 2083 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 932 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2007 | 3052 | 0.030 |
Why?
|
Demography | 1 | 2020 | 1641 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 6307 | 0.030 |
Why?
|
China | 1 | 2021 | 2386 | 0.030 |
Why?
|
Respiratory Sounds | 1 | 2018 | 706 | 0.030 |
Why?
|
Perception | 1 | 2021 | 1205 | 0.030 |
Why?
|
Feces | 1 | 2020 | 1504 | 0.030 |
Why?
|
Health Behavior | 1 | 2005 | 2649 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2354 | 0.030 |
Why?
|
Milk, Human | 1 | 2018 | 490 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1594 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2006 | 4405 | 0.030 |
Why?
|
Social Class | 1 | 2022 | 2007 | 0.030 |
Why?
|
Students | 1 | 2003 | 1736 | 0.030 |
Why?
|
Models, Biological | 1 | 2009 | 9441 | 0.030 |
Why?
|
Phenotype | 1 | 2011 | 16706 | 0.030 |
Why?
|
Arthritis | 1 | 2018 | 676 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 13639 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2006 | 4642 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1959 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15833 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 2015 | 416 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1461 | 0.020 |
Why?
|
Antidepressive Agents | 1 | 2022 | 2899 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2011 | 276 | 0.020 |
Why?
|
Breast Feeding | 1 | 2018 | 1363 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2021 | 2778 | 0.020 |
Why?
|
Urban Population | 2 | 2009 | 2040 | 0.020 |
Why?
|
Immunization | 1 | 2013 | 1218 | 0.020 |
Why?
|
Chronic Disease | 2 | 2020 | 9351 | 0.020 |
Why?
|
Hemorrhage | 1 | 2020 | 3461 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10069 | 0.020 |
Why?
|
Gastroesophageal Reflux | 1 | 2015 | 833 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1367 | 0.020 |
Why?
|
Disease Progression | 1 | 2024 | 13614 | 0.020 |
Why?
|
Laparoscopy | 1 | 2018 | 2039 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2779 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10567 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5019 | 0.020 |
Why?
|
Communication Barriers | 1 | 2009 | 418 | 0.020 |
Why?
|
DNA Probes, HPV | 1 | 2005 | 21 | 0.020 |
Why?
|
snRNP Core Proteins | 1 | 2004 | 21 | 0.020 |
Why?
|
Ribonucleoprotein, U1 Small Nuclear | 1 | 2004 | 36 | 0.010 |
Why?
|
Ribonucleoproteins, Small Nuclear | 1 | 2004 | 71 | 0.010 |
Why?
|
Anti-Allergic Agents | 1 | 2005 | 153 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 14637 | 0.010 |
Why?
|
Texas | 1 | 2003 | 410 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22224 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2007 | 1188 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2004 | 1696 | 0.010 |
Why?
|
Immunoblotting | 1 | 2004 | 1643 | 0.010 |
Why?
|
Tumor Virus Infections | 1 | 2003 | 438 | 0.010 |
Why?
|
Autoantigens | 1 | 2004 | 883 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 2470 | 0.010 |
Why?
|
Hepacivirus | 1 | 2007 | 1343 | 0.010 |
Why?
|
Simplexvirus | 1 | 2003 | 806 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3805 | 0.010 |
Why?
|
Universities | 1 | 2003 | 1000 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2009 | 2040 | 0.010 |
Why?
|
Adolescent Behavior | 1 | 2005 | 1185 | 0.010 |
Why?
|
Body Weight | 1 | 2007 | 4624 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2006 | 2643 | 0.010 |
Why?
|
Diet | 1 | 2013 | 8085 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2004 | 2223 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2006 | 14745 | 0.010 |
Why?
|
Mice | 1 | 2013 | 81792 | 0.000 |
Why?
|